Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results

Abstract excerpt

The combination of ponatinib, a third-generation BCR::ABL1 tyrosine kinase inhibitor, with hyper-CVAD chemotherapy resulted in high rates of complete molecular remissions and survival, without the need for stem cell transplantation (SCT) in most patients with Philadelphia chromosome(Ph)-positive acute lymphocytic leukemia (ALL). Confirming these results in a large cohort of patients with longer follow-up would...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Lymphoblastic Leukemia research
• Share to Chronic Lymphocytic Leukemia Research
• Share to Chronic Myeloid Leukemia Treatments